Oncology Views & Analysis

Views & Analysis

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Oncology

Astellas’ banner year and focused R&D strategy, with Adam Pe...

At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.

Oncology

pharmaphorum podcast Episode 241, Mohit Manrao, AstraZeneca

On AI and equity in the cancer setting, with Mohit Manrao

Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at AstraZeneca, and president of the AstraZeneca Foundation.

Oncology

Unlocking the future of epigenetics, with Carlos Buesa

Carlos Buesa, CEO of Oryzon Genomics, discusses exploring how epigenetics is reshaping the landscape of oncology and CNS therapies.

Oncology

Expanding the haematology toolkit: Insights and operational ...

With over 8,200 abstracts accepted, ASH 2025 showcased breakthroughs in sickle cell disease, platelet disorders, and next-generation cell therapies.

Oncology

pharmaphorum podcast Episode 238, Andrew Newland, ANGLE

Aligning with national efforts to modernise cancer diagnosti...

Andrew Newland, former CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.

Engineering “smarter” cells, with Tim Lu

Astellas’ banner year and focused R&D strategy, with Adam Pe...

On AI and equity in the cancer setting, with Mohit Manrao

Unlocking the future of epigenetics, with Carlos Buesa

Expanding the haematology toolkit: Insights and operational ...

Aligning with national efforts to modernise cancer diagnosti...

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks